{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:21:52Z","timestamp":1788380512433,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016646","name":"HCA Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.06.007","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:45:06Z","timestamp":1781801106000},"page":"e1104-e1114.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3441-8387","authenticated-orcid":false,"given":"Samuel","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Zaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Carilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishak A.","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2026.06.007_bib0001","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2025.05.024","article-title":"2025 Concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"86","author":"Gilbert","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.clml.2026.06.007_bib0002","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.soard.2023.01.025","article-title":"Excess body fatness and cancer risk: a summary of the epidemiologic evidence","volume":"19","author":"Patel","year":"2023","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"10.1016\/j.clml.2026.06.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3520","article-title":"Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis","volume":"4","author":"Petrelli","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.clml.2026.06.007_bib0004","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/annonc\/mdz045","article-title":"Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies","volume":"30","author":"Abar","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.06.007_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041680","article-title":"Diabetes, antidiabetic medications and cancer risk in type 2 diabetes: focus on SGLT-2 inhibitors","volume":"22","author":"D\u0105browski","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.clml.2026.06.007_bib0006","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s00125-011-2423-y","volume":"55","author":"Favaro","year":"2012","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.clml.2026.06.007_bib0007","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.clml.2026.06.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.clml.2026.06.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.0802","article-title":"Hematologic cancers among patients with type 2 diabetes prescribed GLP-1 receptor agonists","volume":"8","author":"Ashruf","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.clml.2026.06.007_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/87551225241266773","article-title":"Utilization of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitors at the Veterans Health Administration","volume":"40","author":"Krishnan","year":"2024","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.clml.2026.06.007_sbref0011","series-title":"Va Hsr Res 13-457","year":"2008"},{"issue":"4","key":"10.1016\/j.clml.2026.06.007_bib0012","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.clml.2026.06.007_sbref0013","series-title":"Healthcare Cost and Utilization Project (HCUP)","year":"2024"},{"key":"10.1016\/j.clml.2026.06.007_sbref0014","series-title":"Databases and Related Tools from the Healthcare Cost and Utilization Project (HCUP)","author":"Elixhauser","year":"2012"},{"issue":"6","key":"10.1016\/j.clml.2026.06.007_bib0015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.clml.2026.06.007_bib0016","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/gerona\/gly232","article-title":"The burden of frailty among U.S. Veterans and its association with mortality, 2002-2012","volume":"74","author":"Orkaby","year":"2019","journal-title":"J Gerontol A"},{"issue":"4","key":"10.1016\/j.clml.2026.06.007_bib0017","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/1475-6773.00165","article-title":"Improved comorbidity adjustment for predicting mortality in Medicare populations","volume":"38","author":"Schneeweiss","year":"2003","journal-title":"Health Serv Res"},{"issue":"6","key":"10.1016\/j.clml.2026.06.007_bib0018","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clml.2026.06.007_bib0019","unstructured":"Semaglutide injection criteria for use July 2022 VA pharmacy benefits management services, medical advisory panel, and VISN pharmacist executives. Available at: https:\/\/www.va.gov\/formularyadvisor\/DOC_PDF\/CFU_Semaglutide_OZEMPIC_Jul22a.pdf Accessed December 22, 2023."},{"issue":"4","key":"10.1016\/j.clml.2026.06.007_bib0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1536867X0200200403","article-title":"Estimation of average treatment effects based on propensity scores","volume":"2","author":"Becker","year":"2002","journal-title":"Stata J"},{"key":"10.1016\/j.clml.2026.06.007_bib0021","author":"Leuven"},{"issue":"11","key":"10.1016\/j.clml.2026.06.007_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/biom15111622","article-title":"Divergent risks of hematologic malignancies associated with GLP-1 receptor agonists and SGLT2 inhibitors: preliminary findings from a pilot network meta-analysis","volume":"15","author":"Lin","year":"2025","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.clml.2026.06.007_bib0023","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab"},{"issue":"9470","key":"10.1016\/j.clml.2026.06.007_bib0024","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(05)66461-6","article-title":"Multiplicity in randomised trials I: endpoints and treatments","volume":"365","author":"Schulz","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clml.2026.06.007_bib0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.clml.2026.06.007_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.33326","article-title":"One-year weight reduction with semaglutide or liraglutide in clinical practice","volume":"7","author":"Gasoyan","year":"2024","journal-title":"JAMA Network Open"},{"issue":"10","key":"10.1016\/j.clml.2026.06.007_bib0027","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1681\/ASN.2007020199","article-title":"Evaluation of the modification of diet in renal disease study equation in a large diverse population","volume":"18","author":"Stevens","year":"2007","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:57:57Z","timestamp":1788379077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2152265026001801"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}